KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals.

Sophy Denker, Aitomi Bittner, Mareike Frick, Julia Kase, Jörg Hoffmann, Corinna Trenker, Ulrich Keller, Christian Bogner, Andreas Hüttmann, Jan Dürig, Martin Janz, Stephan Mathas, Reinhard Marks, Ulrike Krohn, Il-Kang Na, Lars Bullinger, Clemens A Schmitt

Leuk Lymphoma 63(1) 84-92

PMID34414850
PMCID-
DOI10.1080/10428194.2021.1964024
发表日期2021-08-20
摘要

摘要

Diffuse large-cell B-cell lymphoma (DLBCL) is the most common lymphoid malignancy. About 30-40% of the patients will not be cured by standard Rituximab (R)-CHOP-like immune-chemotherapy, and many of them experience relapse and eventually succumb to their disease. Enhancing first-line efficacy in patients at higher risk, among them many elderly, is key to improve long-term outcomes. Numerous attempts to combine R-CHOP with targeted agents failed in large randomized phase III trials. The addition of Ibrutinib enhanced survival in younger patients, but increased toxicity across all age groups, especially in the elderly. Older DLBCL patients impose particular challenges, since they often present with more advanced disease, and exhibit treatment-relevant comorbidities. ImbruVeRCHOP trial aims at identifying patients who need that benefit from rationally augmented first-line regimens without experiencing overt toxicity and detecting their molecular signatures of response. This first analysis presents encouraging feasibility, safety, and preliminary response data in elderly high-risk DLBCL patients.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。